Osteomyelitis Market Analysis

Global Osteomyelitis Market Overview

Osteomyelitis Market Size was valued at USD 0.12 Billion in 2023. The Global Osteomyelitis industry is projected to grow from USD 0.21 Billion in 2024 to USD 1.73 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.47% during the forecast period (2024 - 2032).

In the recent years, the prevalence of osteomyelitis has increased, providing favorable backgrounds for the market to grow. According to NCBI in 2016 the total annual occurrence rate of osteomyelitis was 13 per 100,000 (acute osteomyelitis eight and subacute osteomyelitis five per 100,000) globally. Due to the increasing prevalence of osteomyelitis, the market will witness huge demand for treatments, thus, driving the global osteomyelitis market.

Moreover, in 2016, the International Journal of Environmental Research and Public Health stated that the estimated occurrence rate of acute osteomyelitis is about eight cases per 100,000 children/year. According to the U.S. Census Bureau age projection sheet of 2017–2050, the child population is estimated to increase from 73.8 million in 2017 to 79.9 million by 2050. Moreover, according to the World Journal of Diabetes in 2017, diabetic patients are at a higher risk for osteomyelitis. In the recent, years, the prevalence of the osteomyelitis has increased. As per the American Diabetes Association in 2015, ~30.3 million Americans accounting for 9.4% of the population within the region had diabetes. The prevalence of diabetes is estimated to drive the market by increasing the susceptible population.

However, factors such as the limited availability of treatments, risks associated with surgeries, and low healthcare expenditure in the middle and low-income countries are estimated to hinder the market growth during the forecast period.

Locate Bio, an orthobiologics-focused regenerative medicine company developing CognitOss for chronic osteomyelitis or bone infection, has been awarded Breakthrough Device Designation from the Food and Drug Administration. Osteomyelitis is a developing inflammation of bone, usually due to bacteria, and accounts for 50% of non-traumatic amputations. In the treatment of this condition at present, surgeons, besides having to surgically debride, administer high-dose antibiotics over a prolonged time, but in case of large defects – they will have to perform a secondary surgery just to take out the non-resorbable bone graft. On the other hand, Cognitoss aims at providing surgeons with a single surgery option that combines fully resorbable bone grafts with high-quality fracture healing attributes and special dual-phasic release of antibiotics first released in large numbers at the infection site, then followed by controlled releases that will stop re-infection.

Melinta Therapeutics (Melinta) announced in July 2021 that it has launched KIMYRSA™ (oritavancin). It is a lipoglycopeptide antibiotic that contains a full course dose for acute bacterial skin and skin structure infections (ABSSSI) within a one-hour infusion of 1,200 mg. Last month, the FDA approved KIMYRSA on March 12th for adult patients who have ABSSSI caused by designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).

Osteomyelitis Market Segmentation

The global osteomyelitis market is segmented on the basis of type, diagnosis, treatment, and end-user.

The osteomyelitis market, by type, is further segmented by duration, pathogenesis, and others.  The duration segment is sub-segmented into acute and chronic. The pathogenesis segment is sub-segmented into trauma, contiguous spread, and others. By diagnosis, the market is categorized into physical examination, blood tests, imaging tests, bone biopsy, and others. The blood tests segment is sub-segmented into Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR), and C-Reactive Protein (CRP). The imaging segment is sub-segmented into X-rays, Computerized Tomography (CT) scan, and Magnetic Resonance Imaging (MRI). By treatment, the market is segmented into antibiotics and surgery. The antibiotics segment is sub-segmented into ceftriaxone, nafcillin, ceftazidime, and others. On the basis of end-user, the market is segmented into hospitals and clinics, research organizations, diagnostic diseases, and others.

By region, the global osteomyelitis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players in the Osteomyelitis Market

• Allergan Plc (Republic of Ireland)


• CrystalGenomics Inc (South Korea)


• Debiopharm International SA (Lausanne)


• Motif Bio Plc (London)


• Nabriva Therapeutics AG (Dublin)


• Vyome Biosciences Pvt Ltd (India)


• F. Hoffmann-La Roche AG (Switzerland)


• Koninklijke Philips N.V. (Netherlands)


• General Healthcare (U.S.)


• Siemens AG (Germany)


• Toshiba Corporation (Japan)


• Shimadzu Corporation (Japan)


• Samsung Electronics Co., Ltd. (South Korea)


• Neusoft Medical Systems Co., Ltd. (China)


• Medtronic plc (Ireland)


• Shenzhen Anke High-tech Co., Ltd. (Hong Kong)

Regional Market Summary

Global Osteomyelitis Market Share (%), by Region, 2017

Sources: Journal of Bone and Joint Surgery journal, U.S. Census Bureau, International Journal of Biological Sciences, Indian Brand Equity Foundation, Diabetes UK, Annual Reports, Press Release, White Paper, And Company Presentation

The Americas dominates the global market for osteomyelitis owing to the huge patient population and increasing healthcare expenditure. As per a study published in the International Journal of Biological Sciences in 2015, diabetic patients have higher risks for osteomyelitis. According to the Centers for Disease Control and Prevention in 2017, approximately 30.3 million people, accounting for ~9.4% of the total U.S. population were estimated to suffer from diabetes within the U.S. in 2015.

In 2017, it was estimated that Europe stood second in the global osteomyelitis market. Factors such as the increasing prevalence of osteomyelitis, the presence of developed healthcare industry, and rising government support provide favorable backgrounds for the market to grow. According to the Office for National Statistics in 2015, the government-financed healthcare expenditure accounted for 79.5% of the total spending on healthcare. The government support is estimated to drive the market by enabling the patients’ reach for expensive surgeries.

Asia Pacific was estimated to be the fastest growing region for the global osteomyelitis market in 2017. According to the Indian Brand Equity Foundation in 2017, medical tourism in India is likely to reach a whopping USD 9 billion by 2020 from USD 3 billion in 2015. This increasing medical tourism boosts the Asia Pacific market for osteomyelitis. Moreover, the increasing prevalence of diabetes and an expanding healthcare sector within the region fuel the market within the region.

On the other hand, the Middle East and Africa holds the least share in the global osteomyelitis market. The presence of poor economies, stringent government policies, and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to the presence of developed economies such as Kuwait, Qatar, Dubai, and others.

Research Methodology

Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.

Primary Research

Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

Secondary Research 

Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global osteomyelitis market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.

Global Osteomyelitis Market Segmentation and Key Market Players

Global Osteomyelitis Market, by Diagnosis and Treatment

• Diagnosis


• Physical Examination


• Blood Tests


• Complete Blood Count (CBC)


• Erythrocyte Sedimentation Rate (ESR)


• C-Reactive Protein (CRP)


• Imaging Tests


• X-rays


• Computerized Tomography (CT) Scan


• Magnetic Resonance Imaging (MRI)


• Others


• Bone Biopsy


• Treatment


• Antibiotics


• Ceftriaxone


• Nafcillin


• Ceftazidime


• Others


• Surgery

Global Osteomyelitis Market, by Pathogenesis

• Trauma


• Contiguous Spread


• Others

Global Osteomyelitis Market, by End-User

• Hospital and Clinics


• Research Organization


• Diagnostic Diseases


• Diagnostic Centers

Global Osteomyelitis Market, by Region

• The Americas


• Europe


• Asia Pacific


• The Middle East & Africa

Global Osteomyelitis Market, by Key Players

• Allergan Plc


• CrystalGenomics Inc


• Debiopharm International SA


• Motif Bio Plc


• Nabriva Therapeutics AG


• Hoffmann-La Roche AG


• Koninklijke Philips N.V.


• General Healthcare


• Siemens AG


• Toshiba Corporation


• Shimadzu Corporation


• Samsung Electronics Co., Ltd.


• Neusoft Medical Systems Co., Ltd.


• Medtronic plc


• Shenzhen Anke High-tech Co., Ltd.

Intended Audience

• Pharmaceutical companies


• Biotechnological institutes


• Government and private laboratories


• Research and Development (R&D) companies


• Medical research laboratories


• Market research and consulting service providers